drugset / Trial / NCT00017303

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

NCT00017303 ↗

Phase 2 Unknown Cytran
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.

Timeline

Start
2001-01
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject oglufanide Small molecule — —
Background Carboplatin Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous